|
|
- 2018
525例伴血脂异常IgA肾病患者的临床病理分析
|
Abstract:
摘要 目的： 探究不同血脂类型的IgA肾病患者的临床病理表现的差异.方法: 采用横断面研究设计,纳入525例IgA肾病患者的性别、基线年龄、基线病程、基线血压、高血压病史、血肌酐、eGFR、尿酸、24 h小时尿蛋白定量、尿红细胞计数、血清白蛋白、血脂、Katafuchi半定量病理积分系统(包括小球积分、小管-间质积分、血管积分)等临床病理资料,根据血脂结果将患者分为血脂正常组、高胆固醇血症组、高甘油三酯血症组、低高密度脂蛋白组,分别比较各组临床病理指标的差异.结果: 高甘油三酯血症组的间质纤维化积分、小管萎缩积分、小管间质积分、血管壁增厚积分、血管积分、katafuchi总积分高于血脂正常组;其小球增殖积分低于高胆固醇血症组;而血管壁增厚积分高于高胆固醇血症组.结论: 不同血脂异常类型的IgA肾病患者的病理损害程度并不完全相同,其中高甘油三酯血症可能对肾脏病理改变影响较大.
| [1] | LI L S, LIU Z H.Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies[J]. Kidney Int, 2004,66(3):920-923. |
| [2] | ZHOU F D, ZHAO M H, ZOU W Z, et al.The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre[J]. Nephrol Dial Transplant, 2009,24(3):870-876. |
| [3] | 李瑜祯, 贾汝汉, 刘红燕. 伴有高脂血症的IgA肾病临床和病理分析[J]. 临床肾脏病杂志, 2011,11(4):157-159. |
| [4] | Li Y Z, JIA R H, LIU H Y.Clinical and pathological analysis of IgA nephropathy associated with hyperlipidemia[J]. Journal of Clinical Nephrology, 2011,11(4): 157-159. |
| [5] | 刘擘, 曾玉纯, 李劲高, 等. 伴血脂异常的 IgA 肾病的临床及病理特征[J]. 中华临床医师杂志(电子版), 2015,(14):2669-2672. |
| [6] | 常永超, 江涛, 李维, 等. 不同年龄成年体检者血糖和血脂的变化特点[J]. 河南科技大学学报(医学版), 2009,27(2):146-147. |
| [7] | CHANG Y C, JIANG T, LI W, et al.Characteristics of blood glucose and blood lipids in adults of different ages[J]. Journal of Henan University of Science and Technology (Medical Edition), 2009,27(2): 146-147. |
| [8] | ZHENG L J, HE F P.LOX-1 and hypertension, hyperlipidemia correlation research progress[J]. Molecular Diagnosis and Treatment Journal, 2012,4(1): 54-58. |
| [9] | 殷玥琪, 杨立刚, 孙桂菊. 高脂血症与高血压相关性及其代谢异常研究进展[J]. 中国老年学杂志, 2014,34(5):1414-1417. |
| [10] | YIN Y Q, YANG L G, SUN G J.Hyperlipidemia and hypertension and abnormal metabolism research progress of[J]. Chinese Journal of Gerontology, 2014,34(5): 1414-1417. |
| [11] | MURANO T, MATSUMURA R, MISAWA Y, et al.Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg-->Cys) from a patient with lipoprotein glomerulopathy[J]. Metabolism, 2002,51(2):201-205. |
| [12] | VAZIRI N D.Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences[J]. Am J Physiol Renal Physiol, 2006,290(2):F262-F272. |
| [13] | BOLTON C H, DOWNS L G, VICTORY J G, et al.Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines[J]. Nephrol Dial Transplant, 2001,16(6):1189-1197. |
| [14] | MOORHEAD J F, CHAN M K, EL-NAHAS M, et al.Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease[J]. Lancet, 1982,2(8311):1309-1311. |
| [15] | MORIYAMA T, OSHIMA Y, TANAKA K, et al.Statins stabilize the renal function of IgA nephropathy[J]. Ren Fail, 2014,36(3):356-360. |
| [16] | RAUEN T, EITNER F, FITZNER C, et al.Intensive Supportive Care plus Immunosuppression in IgA Nephropathy[J]. N Engl J Med, 2015,373(23):2225-2236. |
| [17] | DONDIO J V, GRANDE J P.IgA nephropathy[J]. N Engl J Med, 2002,347(10):738-748. |
| [18] | KOVACS T, VAS T, KOVESDY C P, et al.Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy[J]. Clinical Kidney Journal, 2013,6(4):395-401. |
| [19] | 中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007,35(5):390-419. |
| [20] | Joint Committee on the development of guidelines for the prevention and treatment of dyslipidemia in Chinese adults. Guidelines for the prevention and treatment of dyslipidemia in Chinese adults[J]. Chinese Journal of Cardiology, 2007,35(5):390-419. |
| [21] | KATAFUCHI R, KIYOSHI Y, OH Y, et al.Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation[J]. Clin Nephrol, 1998,49(1):1-8. |
| [22] | 沈姗, 柴华旗. 高脂血症与IgA肾病临床病理的相关性分析[J]. 中国血液流变学杂志, 2013,(2):268-270, 273. |
| [23] | 刘小平, 徐薇. 不同年龄组人群血脂水平的观察与对比[J]. 南京铁道医学院学报, 1999,(3):186-187. |
| [24] | NAKANO A, INOUE N, SATO Y, et al.LOX-1 mediates vascular lipid retention under hypertensive state[J]. J Hypertens, 2010,28(6):1273-1280. |
| [25] | 卢光娅, 张玲. 高尿酸血症与代谢综合征的相互影响及研究进展[J]. 重庆医学, 2011,40(15):1542-1543. |
| [26] | MYLES J L.Diagnostic atlas of renal pathology: a companion to Brenner & Rector's the kidney, 9th edition[M]. Elsevier/Saunders, 2012:923. |
| [27] | ZHANG G Y, FU P, YUAN W J.Progress in the study of renal toxicity of triglycerides[J]. Foreign Medicine (urinary tract fascicle), 2003,23(3): 322-325. |
| [28] | BJORNEKLETT R, VIKSE B E, BOSTAD L, et al.Long-term risk of ESRD in IgAN; validation of Japanese prognostic model in a Norwegian cohort[J]. Nephrol Dial Transplant, 2012,27(4):1485-1491. |
| [29] | LIU B, ZENG Y C, LI J G, et al.Clinical and pathological features of IgA nephropathy with dyslipidemia[J]. Chinese Journal of Clinicians (Electronic Edition), 2015(14): 2669-2672. |
| [30] | CARR M C, HOKANSON J E, ZAMBON A, et al.The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity[J]. J Clin Endocrinol Metab, 2001,86(6):2831-2837. |
| [31] | YAMAGUCHI M, IGARASHI A, UCHIYAMA S, et al.Hyperlipidemia is induced in regucalcin transgenic rats with increasing age[J]. Int J Mol Med, 2004,14(4):647-651. |
| [32] | 吴剑敏, 吴可贵, 陈纯娴, 等. 代谢综合征早期肾损害[J]. 中外健康文摘, 2010,7(15):7-8. |
| [33] | WU J M, WU K G, CHEN C X, et al.Early renal damage of metabolic syndrome[J]. Chinese and Foreign Health Abstracts, 2010,7(15): 7-8. |
| [34] | MYLLYMAKI J, SYRJANEN J, HELIN H, et al.Vascular diseases and their risk factors in IgA nephropathy[J]. Nephrol Dial Transplant, 2006,21(7):1876-1882. |
| [35] | SYRJANEN J, MUSTONEN J, PASTERNACK A.Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy[J]. Nephrol Dial Transplant, 2000,15(1):34-42. |
| [36] | GOTO M, KAWAMURA T, WAKAI K, et al.Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm[J]. Nephrol Dial Transplant, 2009,24(4):1242-1247. |
| [37] | SHEN S, CHAI H Q.Hyperlipidemia and IgA nephropathy clinical pathological correlation analysis[J]. Chinese Blood Rheology Magazine, 2013,(2): 268-270, 273. |
| [38] | 秦菊, 李璐, 廖蕴华. 高脂血症对原发性IgA肾病的临床及病理影响[J]. 微创医学, 2015,10(3):287-289. |
| [39] | QIN J, LI L, LIAO Y H.Clinical and pathological effects of hyperlipidemia on primary IgA nephropathy[J]. Minimally Invasive Medicine, 2015,10(3): 287-289. |
| [40] | LIU X P, XU W.Observation and comparison of blood lipid levels in different age groups[J]. Journal of Nanjing Railway Medical College, 1999,(3): 186-187. |
| [41] | 郑礼杰, 何凤屏. LOX-1与高血压、高脂血症的相关性研究进展[J]. 分子诊断与治疗杂志, 2012,4(1):54-58. |
| [42] | LU G Y, ZHANG L.Interaction and research progress of hyperuricemia and metabolic syndrome[J]. Chongqing Medical Sciences, 2011,40(15): 1542-1543. |
| [43] | TSOULI S G, LIBEROPOULOSi E N, MIKHAILIDIS D P, et al.Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?[J]. Metabolism, 2006,55(10):1293-1301. |
| [44] | 张国莹, 傅鹏, 袁伟杰. 甘油三酯“肾毒性”研究进展[J]. 国外医学(泌尿系统分册), 2003,23(3):322-325. |
